SOHO 2025
Michael J. Mauro, MD, on the ENABLE Study in Heavily Pretreated Patients With CML
Michael J. Mauro, MD, of Memorial Sloan Kettering Cancer Center, reviews findings from the phase Ia/Ib ENABLE study, which evaluated ELVN-001, a highly selective, active-site inhibitor designed to tar...
Nirav N. Shah, MD, MSHP, on a BTK Degrader in Relapsed or Refractory CLL
Nirav N. Shah, MD, MSHP, of the Medical College of Wisconsin, presents results from a phase Ia study of bexobrutideg, a Bruton’s tyrosine kinase (BTK) degrader. The agent was tested in a heavily pretr...
Farhad Ravandi, MD, on AML: Highlights of Ongoing Research
Farhad Ravandi, MD, provides an overview of acute myeloid leukemia (AML) research highlighted in a session at SOHO, including data on menin inhibitors in NPM1-mutated disease; FLT3 inhibitors in FLT3-...
Elias Jabbour, MD, on CAR T-Cell Therapy for Adult Patients With Relapsed/Refractory B-Cell ALL
Elias Jabbour, MD, discusses long-term findings and predictors of sustained remission among adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) who did not undergo a stem...
